Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11051MR)

This product GTTS-WQ11051MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11051MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2530MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ9569MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ10331MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ5928MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ7371MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ8874MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ14216MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW